Skip to main content
. 2020 Nov 5;12(11):1057. doi: 10.3390/pharmaceutics12111057

Figure 4.

Figure 4

Water ingress profiles of TAFHF-CO (a), TAFHF-PEG600 (b), TAFFB-CO (c), and TAFFB-SO (d) formulations within PCL implants exposed to simulated physiological conditions (37 °C, PBS). Two-line model (depicted in black lines) has been applied to TAFHF-CO, TAFFB-CO and TAFFB-SO formulations in mass ratios of 2:1.